Kathryn Coyle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10394422/publications.pdf

Version: 2024-02-01

1040056 888059 21 418 9 17 citations h-index g-index papers 21 21 21 786 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. Value in Health, 2013, 16, 498-506.	0.3	127
2	Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open, 2014, 4, e004301-e004301.	1.9	93
3	EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. BMJ Open, 2014, 4, e006945.	1.9	29
4	Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy. JACC: Clinical Electrophysiology, 2018, 4, 660-668.	3.2	27
5	Estimates of effectiveness and reach for †return on investment†m modelling of smoking cessation interventions using data from England. Addiction, 2018, 113, 19-31.	3.3	20
6	Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation. Addiction, 2018, 113, 7-18.	3.3	20
7	Costâ€effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD. Addiction, 2018, 113, 65-75.	3.3	19
8	Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. Value in Health, 2017, 20, 586-592.	0.3	16
9	Is it costâ€effective to provide internetâ€based interventions to complement the current provision of smoking cessation services in the Netherlands? An analysis based on the EQUIPTMOD. Addiction, 2018, 113, 87-95.	3.3	15
10	Estimates of costs for modelling return on investment from smoking cessation interventions. Addiction, 2018, 113, 32-41.	3.3	9
11	Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). European Heart Journal Cardiovascular Imaging, 2021, 22, 1083-1090.	1.2	9
12	Cost-effectiveness of offering an area-level financial incentive on breast feeding: a within-cluster randomised controlled trial analysis. Archives of Disease in Childhood, 2020, 105, archdischild-2018-316741.	1.9	8
13	Assessment of cost-effective changes to the current and potential provision of smoking cessation services: an analysis based on the EQUIPTMOD. Addiction, 2018, 113, 96-105.	3.3	7
14	Costâ€effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD. Addiction, 2018, 113, 52-64.	3.3	6
15	A utility of model input uncertainty analysis in transferring tobacco controlâ€related economic evidence to countries with scarce resources: results from the EQUIPT study. Addiction, 2018, 113, 42-51.	3.3	5
16	Costâ€effectiveness of possible future smoking cessation strategies in Hungary: results from the EQUIPTMOD. Addiction, 2018, 113, 76-86.	3.3	5
17	Bendamustine and Rituximab Versus Conventional Chemoimmunotherapy As a Frontline Treatment for Patients with Indolent B-Cell Lymphoma: A Cost-Effectiveness Analysis. Blood, 2016, 128, 1186-1186.	1.4	3
18	Designing economic evaluations to facilitate optimal decisions: the need to avoid bias. ClinicoEconomics and Outcomes Research, 2016, 8, 73.	1.9	0

KATHRYN COYLE

#	Article	IF	CITATIONS
19	ROI Analysis: Making Policy Impacts. , 2017, , 139-157.		O
20	A Journey to Real-World Decision Problems. , 2017, , 93-101.		0
21	Where's Next for Public Health ROI Research?. , 2017, , 159-169.		O